ABIOMED, Inc. (NASDAQ:ABMD) reported Q1 2018 earnings this Morning, coming in at $0.82 per share, beating Wall Street’s estimates of $0.42 per Share. Revenue for the quarter came in at $132.47 million beating analyst estimates of $130.83 million
Analyst Coverage For ABIOMED, Inc. (NASDAQ:ABMD)
These are 1 Hold Rating, 6 Buy Ratings .
The current consensus rating for ABIOMED, Inc. (NASDAQ:ABMD) is Buy (Score: 2.86) with a consensus target price of $150.00 , a potential (3.39% upside)Recent Insider Trading for ABIOMED, Inc. (NASDAQ:ABMD)
- On 5/16/2017 Michael G Howley, VP, sold 18,279 with an average share price of $133.56 per share and the total transaction amounting to $2,441,343.24.
- On 5/8/2017 David M Weber, COO, sold 21,250 with an average share price of $130.89 per share and the total transaction amounting to $2,781,412.50.
- On 5/8/2017 Dorothy E Puhy, Director, sold 13,500 with an average share price of $131.12 per share and the total transaction amounting to $1,770,120.00.
- On 5/8/2017 Michael G Howley, VP, sold 600 with an average share price of $132.84 per share and the total transaction amounting to $79,704.00.
- On 3/17/2017 Andrew J Greenfield, VP, sold 10,000 with an average share price of $124.00 per share and the total transaction amounting to $1,240,000.00.
- On 12/13/2016 Dorothy E Puhy, Director, sold 8,000 with an average share price of $120.00 per share and the total transaction amounting to $960,000.00.
Recent Trading for ABIOMED, Inc. (NASDAQ:ABMD) Shares of ABIOMED, Inc. closed the previous trading session at 143.03 down -2.05 -1.41% with 731,352 shares trading hands.